Somanetics Corp (NASDAQ:SMTS)
Develops, manufactures and markets the INVOS Cerebral Oximeter, the only non-invasive patient monitoring system commercially available in the United States that continuously measures changes in the blood oxygen level in the adult brain.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
untouched market, leads area with its product
Recs
this company does something unique, it has a healthy balance sheet and good potential
Recs
SMTS may ride high for the next year. However, in the 2 to 5 yr. this stock will underperform as competition will erode gross margins and market share over time
Recs
unique product
Recs
Strong moat. Net cash 40% of market cap. Expanding market application.
Recs
Buy if it hits $12. Nice P/B at 2 but I like a lower P/E in this market. No debt, god margins & mgt but no dividend. I think medical is going to be slow until the coming shakeup in insurance begins to take shape. I'd want a bargain price and I missed it in 4/08. I like anything selling at 1/3 of it's 52 week high.
Recs
Guru momentum
Recs
Will pitch this one a little later.
Recs
Given that the company has, still, some available cash left to continue (re) purchasing some of its stock, if they continue on this trail, I believe that the market will reward them.
Recs
Will touch $28 in few months
Recs
Great business model solid margins nothing but growth ahead.
Recs
This is the Netflix of Oxygen monitoring. Not too sophisticated, one really convenient product, easy to sell and easy for hospitals to buy. Patients don't get jabbed-- Heck, maybe I will just get started monitoring myself now...
Recs
great company. Stock gets ahead of itself every once in a while, but eanrings growth has been consistent.
Recs
This company should be bought by Johnson andJohnson
Recs
Good consistent growth with PEG < 1. And what's not to like about non-invasive monitoring systems.
Recs
strong margins and growth, good liquidity and a niche market in healthcare, should be stong for two years until the next best thing comes out.
Recs
pumping all pedals, but no Mad Money word
Recs
This is a well run company with a steady growth pattern. Keep it for the long haul and you won't be sorry.
Recs
You know, I feel I could use one of their devices for my own pre-frontal cortex at least half the time.
This stock has popped up multiple times in my past 18 months of stock screening, so i recognize it. However, I got the idea from Penny to put it in Caps.
Recs
growth market
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 27 : 1 2 Next »